Welcome to LookChem.com Sign In|Join Free

CAS

  • or

705-09-9

Post Buying Request

705-09-9 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

705-09-9 Usage

General Description

2-Difluoromethyl-1H-benzoimidazole is a chemical compound with the molecular formula C8H6F2N2. It is a benzimidazole derivative with two fluorine atoms attached to the carbon in the 2-position of the benzene ring. 2-Difluoromethyl-1H-benzoimidazole has potential applications in pharmaceutical research and drug development due to its unique structure and potential biological activity. It may be used as a precursor in the synthesis of various pharmaceutical compounds and could have potential therapeutic properties. Further studies may be needed to fully understand its potential uses and properties in the pharmaceutical and chemical industries.

Check Digit Verification of cas no

The CAS Registry Mumber 705-09-9 includes 6 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 3 digits, 7,0 and 5 respectively; the second part has 2 digits, 0 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 705-09:
(5*7)+(4*0)+(3*5)+(2*0)+(1*9)=59
59 % 10 = 9
So 705-09-9 is a valid CAS Registry Number.
InChI:InChI=1/C8H6F2N2/c9-7(10)8-11-5-3-1-2-4-6(5)12-8/h1-4,7H,(H,11,12)

705-09-9 Well-known Company Product Price

  • Brand
  • (Code)Product description
  • CAS number
  • Packaging
  • Price
  • Detail
  • TCI America

  • (D4763)  2-(Difluoromethyl)benzimidazole  >98.0%(GC)(T)

  • 705-09-9

  • 1g

  • 1,280.00CNY

  • Detail
  • TCI America

  • (D4763)  2-(Difluoromethyl)benzimidazole  >98.0%(GC)(T)

  • 705-09-9

  • 5g

  • 4,490.00CNY

  • Detail

705-09-9SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 12, 2017

Revision Date: Aug 12, 2017

1.Identification

1.1 GHS Product identifier

Product name 2-(difluoromethyl)-1H-benzimidazole

1.2 Other means of identification

Product number -
Other names 2-difluoromethyl-1H-benzimidazole

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:705-09-9 SDS

705-09-9Relevant articles and documents

Silver-Enabled General Radical Difluoromethylation Reaction with TMSCF2H

Yang, Jun,Zhu, Shengqing,Wang, Fang,Qing, Feng-Ling,Chu, Lingling

supporting information, p. 4300 - 4306 (2020/12/25)

A silver-mediated oxidative difluoromethylation of styrenes and vinyl trifluoroborates with TMSCF2H is reported for the first time. This method enables direct and facile access to CF2H-alkenes from abundant alkenes with excellent functional-group compatibility. Moreover, this Ag/TMSCF2H protocol could further enable a series of radical difluoromethylation reactions of a wide array of substrates, offering a generic and complementary platform for the construction of diversified C?CF2H bonds.

Process for production of DFMB derivatives

-

Paragraph 0037, (2015/02/05)

A process for the production of a compound of formula (III) which comprises a step of reacting a compound of formula (I) with an excess amount of a compound of formula (II) in absence of aromatic solvent, wherein n is 0, 1, 2, 3 or 4; X is NH, O or S; eac

QUINAZOLINES AND AZAQUINAZOLINES AS DUAL INHIBITORS OF RAS/RAF/MEK/ERK AND PI3K/AKT/PTEN/MTOR PATHWAYS

-

Page/Page column 59; 60, (2014/10/29)

The present application provides novel quinazolines and azaquinazolines and pharmaceutically acceptable salts thereof. Also provided are methods for preparing these compounds. These compounds are useful in for co-regulating RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways by administering a therapeutically effective amount of one or more of the compounds of formula (I), wherein X, Y, T and R4, and R6 to R8' are defined herein, to a patient. By doing so, these compounds are effective in treating conditions associated with the dysregulation of the RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways. A variety of conditions can be treated using these compounds and include diseases which are characterized by abnormal cellular proliferation. In one embodiment/ the disease is cancer.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 705-09-9